Check Out Our Latest Research Report on IO Biotech IO Biotech Trading Down 2.1 % Shares of IOBT stock opened at $0.98 on Friday. The company has a market cap of $64.84 million, a PE ratio of -0.72 ...

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, has been named to Fast Company’s prestigious list of the World’s Most ...

Shares of IOBT stock opened at $1.07 on Tuesday. IO Biotech has a 12-month low of $0.66 and a 12-month high of $1.79. The business’s 50 day moving average is $0.97 and its two-hundred day moving ...

The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to Cylembio. IO Biotech ...

IO Biotech announced promising findings regarding a novel peptide vaccine designed to counter the immunosuppressive effects of Transforming Growth Factor Beta (TGF-β) in solid tumors. The ...

IO Biotech, a Danish med-tech company, has obtained €57.5 million in venture debt financing from the European Investment Bank, with backing fro ...

Fast Company recognizes 609 organizations across 58 sectors and regions. IO Biotech has been recognized for its potentially game-changing approach to immune-mod • Findings support the ...

Biopharmaceutical company recognized for innovation in the development of immune-modulatory therapeutic cancer vaccines – NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq ...